381 related articles for article (PubMed ID: 34326125)
1. First-in-Humans Evaluation of a PD-L1-Binding Peptide PET Radiotracer in Non-Small Cell Lung Cancer Patients.
Zhou X; Jiang J; Yang X; Liu T; Ding J; Nimmagadda S; Pomper MG; Zhu H; Zhao J; Yang Z; Li N
J Nucl Med; 2022 Apr; 63(4):536-542. PubMed ID: 34326125
[No Abstract] [Full Text] [Related]
2. Sensitive Positron Emission Tomography Imaging of PD-L1 Expression in Human Breast and Lung Carcinoma Xenografts Using the Radiometalated Peptide Ga-68-TRAP-WL12.
Quigley NG; Steiger K; Färber SF; Richter F; Weichert W; Notni J
Mol Pharm; 2024 Apr; 21(4):1827-1837. PubMed ID: 38291706
[TBL] [Abstract][Full Text] [Related]
3. Preclinical evaluation and pilot clinical study of [
Ma X; Zhou X; Hu B; Li X; Yao M; Li L; Qin X; Li D; Yao Y; Hou X; Liu S; Chen Y; Wang Z; Zhou W; Li N; Zhu H; Jia B; Yang Z
Eur J Nucl Med Mol Imaging; 2023 Nov; 50(13):3838-3850. PubMed ID: 37555904
[TBL] [Abstract][Full Text] [Related]
4. Development of novel peptide-based radiotracers for detecting PD-L1 expression and guiding cancer immunotherapy.
Zhu S; Liang B; Zhou Y; Chen Y; Fu J; Qiu L; Lin J
Eur J Nucl Med Mol Imaging; 2024 Feb; 51(3):625-640. PubMed ID: 37878029
[TBL] [Abstract][Full Text] [Related]
5. Noninvasive evaluation of PD-L1 expression using Copper 64 labeled peptide WL12 by micro-PET imaging in Chinese hamster ovary cell tumor model.
Jiang J; Li D; Liu T; Xia L; Guo X; Meng X; Liu F; Wang F; Yang Z; Zhu H
Bioorg Med Chem Lett; 2021 May; 40():127901. PubMed ID: 33705912
[TBL] [Abstract][Full Text] [Related]
6. [
Wang Y; Zhang Y; Chen Y; Wang S; Liu W; Liu Z; Hu M
Eur J Nucl Med Mol Imaging; 2024 May; ():. PubMed ID: 38713298
[TBL] [Abstract][Full Text] [Related]
7. In Vivo Evaluation and Dosimetry Estimate for a High Affinity Affibody PET Tracer Targeting PD-L1.
Rubins DJ; Meng X; McQuade P; Klimas M; Getty K; Lin SA; Connolly BM; O'Malley SS; Haley H; Purcell M; Gantert L; Holahan M; Lindgren J; Eklund P; Ekblad C; Frejd FY; Hostetler ED; González Trotter DE; Evelhoch JL
Mol Imaging Biol; 2021 Apr; 23(2):241-249. PubMed ID: 33098025
[TBL] [Abstract][Full Text] [Related]
8. Preclinical and first-in-human evaluation of
Zhou M; Wang X; Chen B; Xiang S; Rao W; Zhang Z; Liu H; Fang J; Yin X; Deng P; Zhang X; Hu S
Eur J Nucl Med Mol Imaging; 2022 Nov; 49(13):4312-4324. PubMed ID: 35831714
[TBL] [Abstract][Full Text] [Related]
9. Linear Peptide-Based PET Tracers for Imaging PD-L1 in Tumors.
Zhang L; Zhang S; Wu J; Wang Y; Wu Y; Sun X; Wang X; Shen J; Xie L; Zhang Y; Zhang H; Hu K; Wang F; Wang R; Zhang MR
Mol Pharm; 2023 Aug; 20(8):4256-4267. PubMed ID: 37368947
[TBL] [Abstract][Full Text] [Related]
10. PD-L1 PET/CT Imaging with Radiolabeled Durvalumab in Patients with Advanced-Stage Non-Small Cell Lung Cancer.
Smit J; Borm FJ; Niemeijer AN; Huisman MC; Hoekstra OS; Boellaard R; Oprea-Lager DE; Vugts DJ; van Dongen GAMS; de Wit-van der Veen BJ; Thunnissen E; Smit EF; de Langen AJ
J Nucl Med; 2022 May; 63(5):686-693. PubMed ID: 34385342
[TBL] [Abstract][Full Text] [Related]
11. Development of [
Lesniak WG; Mease RC; Chatterjee S; Kumar D; Lisok A; Wharram B; Kalagadda VR; Emens LA; Pomper MG; Nimmagadda S
Mol Imaging; 2019; 18():1536012119852189. PubMed ID: 31187691
[TBL] [Abstract][Full Text] [Related]
12. Study of
Niemeijer AN; Oprea-Lager DE; Huisman MC; Hoekstra OS; Boellaard R; de Wit-van der Veen BJ; Bahce I; Vugts DJ; van Dongen GAMS; Thunnissen E; Smit EF; de Langen AJ
J Nucl Med; 2022 Mar; 63(3):362-367. PubMed ID: 34272316
[TBL] [Abstract][Full Text] [Related]
13. Early Phase I Study of a
Xing Y; Chand G; Liu C; Cook GJR; O'Doherty J; Zhao L; Wong NCL; Meszaros LK; Ting HH; Zhao J
J Nucl Med; 2019 Sep; 60(9):1213-1220. PubMed ID: 30796165
[TBL] [Abstract][Full Text] [Related]
14. Immuno-PET imaging of PD-L1 expression in patient-derived lung cancer xenografts with [
Liu Q; Wang X; Yang Y; Wang C; Zou J; Lin J; Qiu L
Quant Imaging Med Surg; 2022 Jun; 12(6):3300-3313. PubMed ID: 35655844
[TBL] [Abstract][Full Text] [Related]
15. Preclinical development of novel PD-L1 tracers and first-in-human study of [
Zhang Y; Cao M; Wu Y; Malih S; Xu D; Yang E; Younis MH; Lin W; Zhao H; Wang C; Liu Q; Engle JW; Rasaee MJ; Guan Y; Huang G; Liu J; Cai W; Xie F; Wei W
J Immunother Cancer; 2024 Apr; 12(4):. PubMed ID: 38580333
[TBL] [Abstract][Full Text] [Related]
16. PET Imaging of Tumor PD-L1 Expression with a Highly Specific Nonblocking Single-Domain Antibody.
Lv G; Sun X; Qiu L; Sun Y; Li K; Liu Q; Zhao Q; Qin S; Lin J
J Nucl Med; 2020 Jan; 61(1):117-122. PubMed ID: 31253743
[TBL] [Abstract][Full Text] [Related]
17. Negative Correlation Between
Wu L; Liu J; Wang S; Bai M; Wu M; Gao Z; Li J; Yu J; Liu J; Meng X
Front Endocrinol (Lausanne); 2022; 13():913631. PubMed ID: 35846323
[TBL] [Abstract][Full Text] [Related]
18. Peptide-Based
De Silva RA; Kumar D; Lisok A; Chatterjee S; Wharram B; Venkateswara Rao K; Mease R; Dannals RF; Pomper MG; Nimmagadda S
Mol Pharm; 2018 Sep; 15(9):3946-3952. PubMed ID: 30037229
[TBL] [Abstract][Full Text] [Related]
19. In Vivo Imaging of the Programmed Death Ligand 1 by
González Trotter DE; Meng X; McQuade P; Rubins D; Klimas M; Zeng Z; Connolly BM; Miller PJ; O'Malley SS; Lin SA; Getty KL; Fayadat-Dilman L; Liang L; Wahlberg E; Widmark O; Ekblad C; Frejd FY; Hostetler ED; Evelhoch JL
J Nucl Med; 2017 Nov; 58(11):1852-1857. PubMed ID: 28588151
[TBL] [Abstract][Full Text] [Related]
20. Dose escalation biodistribution, positron emission tomography/computed tomography imaging and dosimetry of a highly specific radionuclide-labeled non-blocking nanobody.
Yang Y; Wang C; Wang Y; Sun Y; Huang X; Huang M; Xu H; Fan H; Chen D; Zhao F
EJNMMI Res; 2021 Oct; 11(1):113. PubMed ID: 34718889
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
